Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936950 | 0.84 | PIK3CG (0.36) | SRCPDGFRBABL1PDE2APDE10A | |
| SCHEMBL41638 | 0.76 | PIK3CG (0.43) | SRCPDE2APDE10A | |
| SCHEMBL14936919 | 0.74 | PIK3CG (0.40) | SRCPDGFRBABL1 | |
| SCHEMBL14937276 | 0.73 | PIK3CG (0.34) | SRCPDGFRB | |
| SCHEMBL14936042 | 0.72 | FGFR4 (0.43) | SRCPDGFRBABL1PDE2APDE10A | |
| SCHEMBL14936009 | 0.72 | PIK3CG (0.35) | SRCPDGFRBABL1PDE2APDE10A | |
| SCHEMBL14937044 | 0.72 | PIK3CG (0.33) | SRCPDGFRBABL1PDE2APDE10A | |
| SCHEMBL14936723 | 0.70 | SRC (0.39) | SRC | |
| SCHEMBL14936318 | 0.63 | FGFR4 (0.41) | SRCPDGFRBABL1PDE2APDE10A | |
| SCHEMBL31507885 | 0.61 | TDP2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | SRC 401/4885PDGFRB 803/4885ABL1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.